These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 31067545)

  • 1. Utility of Mesalazine in Familial Adenomatous Polyposis: Clinical Report of Reduction of Polyp Size in Patients with Ulcerative Colitis, and Safety Examination in Familial Adenomatous Polyposis Patients.
    Ishikawa H; Mutoh M; Abe T; Nakajima T; Takeuchi Y; Ezoe Y; Wakabayashi K; Doyama H; Sakai T
    Pharmacology; 2019; 104(1-2):51-56. PubMed ID: 31067545
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemoprevention with low-dose aspirin, mesalazine, or both in patients with familial adenomatous polyposis without previous colectomy (J-FAPP Study IV): a multicentre, double-blind, randomised, two-by-two factorial design trial.
    Ishikawa H; Mutoh M; Sato Y; Doyama H; Tajika M; Tanaka S; Horimatsu T; Takeuchi Y; Kashida H; Tashiro J; Ezoe Y; Nakajima T; Ikematsu H; Hori S; Suzuki S; Otani T; Takayama T; Ohda Y; Mure K; Wakabayashi K; Sakai T
    Lancet Gastroenterol Hepatol; 2021 Jun; 6(6):474-481. PubMed ID: 33812492
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preventive effects of low-dose aspirin on colorectal adenoma growth in patients with familial adenomatous polyposis: double-blind, randomized clinical trial.
    Ishikawa H; Wakabayashi K; Suzuki S; Mutoh M; Hirata K; Nakamura T; Takeyama I; Kawano A; Gondo N; Abe T; Tokudome S; Goto C; Matsuura N; Sakai T
    Cancer Med; 2013 Feb; 2(1):50-6. PubMed ID: 24133627
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of prolonged release budesonide granules in mesalazine-refractory ulcerative colitis: A multi-centre Phase IIa study (TOPICAL-1).
    Fellermann K; Schiefke I; Rácz I; Derova J; Jonaitis L; Wehrum S; Nacak T; Greinwald R
    United European Gastroenterol J; 2020 Dec; 8(10):1186-1195. PubMed ID: 33028169
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses.
    Kruis W; Schreiber S; Theuer D; Brandes JW; Schütz E; Howaldt S; Krakamp B; Hämling J; Mönnikes H; Koop I; Stolte M; Pallant D; Ewald U
    Gut; 2001 Dec; 49(6):783-9. PubMed ID: 11709512
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined oral and rectal mesalazine for the treatment of mild-to-moderately active ulcerative colitis: rapid symptom resolution and improvements in quality of life.
    Probert CS; Dignass AU; Lindgren S; Oudkerk Pool M; Marteau P
    J Crohns Colitis; 2014 Mar; 8(3):200-7. PubMed ID: 24012063
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Long-Term Mesalamine Therapy on Cancer-Associated Gene Expression in Colonic Mucosa of Patients with Ulcerative Colitis.
    Bajpai M; Seril DN; Van Gurp J; Geng X; Alvarez J; Minacapelli CD; Gorin S; Das KK; Poplin E; Cheng J; Amenta PS; Das KM
    Dig Dis Sci; 2019 Mar; 64(3):740-750. PubMed ID: 30478770
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of eflornithine (CPP-1X)/sulindac combination therapy versus each as monotherapy in patients with familial adenomatous polyposis (FAP): design and rationale of a randomized, double-blind, Phase III trial.
    Burke CA; Dekker E; Samadder NJ; Stoffel E; Cohen A
    BMC Gastroenterol; 2016 Aug; 16(1):87. PubMed ID: 27480131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mesalazine allergy in a boy with ulcerative colitis: clinical usefulness of mucosal biopsy criteria.
    Wada S; Kumagai H; Yokoyama K; Ito T; Miyauchi A; Sakamoto S; Imagawa T; Tulyeu J; Tanaka M; Yamagata T
    Clin J Gastroenterol; 2016 Oct; 9(5):302-5. PubMed ID: 27503129
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mesalazine (5-aminosalicylic acid) micropellets show similar efficacy and tolerability to mesalazine tablets in patients with ulcerative colitis--results from a randomized-controlled trial.
    Raedler A; Behrens C; Bias P
    Aliment Pharmacol Ther; 2004 Dec; 20(11-12):1353-63. PubMed ID: 15606398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomised clinical trial: delayed-release oral mesalazine 4.8 g/day vs. 2.4 g/day in endoscopic mucosal healing--ASCEND I and II combined analysis.
    Lichtenstein GR; Ramsey D; Rubin DT
    Aliment Pharmacol Ther; 2011 Mar; 33(6):672-8. PubMed ID: 21255059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of Sulindac and Bexarotene for Prevention of Intestinal Carcinogenesis in Familial Adenomatous Polyposis.
    Bowen CM; Walter L; Borras E; Wu W; Ozcan Z; Chang K; Bommi PV; Taggart MW; Thirumurthi S; Lynch PM; Reyes-Uribe L; Scheet PA; Sinha KM; Vilar E
    Cancer Prev Res (Phila); 2021 Sep; 14(9):851-862. PubMed ID: 34266857
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study.
    Marteau P; Probert CS; Lindgren S; Gassul M; Tan TG; Dignass A; Befrits R; Midhagen G; Rademaker J; Foldager M
    Gut; 2005 Jul; 54(7):960-5. PubMed ID: 15951542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical trial: Effects of an oral preparation of mesalazine at 4 g/day on moderately active ulcerative colitis. A phase III parallel-dosing study.
    Hiwatashi N; Suzuki Y; Mitsuyama K; Munakata A; Hibi T
    J Gastroenterol; 2011 Jan; 46(1):46-56. PubMed ID: 20878425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cell proliferation and apoptotic indices predict adenoma regression in a placebo-controlled trial of celecoxib in familial adenomatous polyposis patients.
    Sinicrope FA; Half E; Morris JS; Lynch PM; Morrow JD; Levin B; Hawk ET; Cohen DS; Ayers GD; Stephens LC;
    Cancer Epidemiol Biomarkers Prev; 2004 Jun; 13(6):920-7. PubMed ID: 15184247
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early symptomatic response and mucosal healing with mesalazine rectal suspension therapy in active distal ulcerative colitis--additional results from two controlled studies.
    Sandborn WJ; Hanauer S; Lichtenstein GR; Safdi M; Edeline M; Scott Harris M
    Aliment Pharmacol Ther; 2011 Oct; 34(7):747-56. PubMed ID: 21848857
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mesalazine Modified-Release Tablet in the Treatment of Ulcerative Colitis in the Active Phase: A Chinese, Multicenter, Single-Blind, Randomized Controlled Study.
    Sun J; Yuan Y
    Adv Ther; 2016 Mar; 33(3):400-9. PubMed ID: 26898569
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Olsalazine versus mesalazine in the treatment of mild to moderate ulcerative colitis.
    Kruis W; Brandes JW; Schreiber S; Theuer D; Krakamp B; Schütz E; Otto P; Lorenz-Mayer H; Ewe K; Judmaier G
    Aliment Pharmacol Ther; 1998 Aug; 12(8):707-15. PubMed ID: 9726382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. What dose of 5-aminosalicylic acid (mesalazine) in ulcerative colitis?
    Riley SA
    Gut; 1998 Jun; 42(6):761-3. PubMed ID: 9691909
    [No Abstract]   [Full Text] [Related]  

  • 20. Once daily MMX mesalazine for the treatment of mild-to-moderate ulcerative colitis: a phase II, dose-ranging study.
    D'Haens G; Hommes D; Engels L; Baert F; van der Waaij L; Connor P; Ramage J; Dewit O; Palmen M; Stephenson D; Joseph R
    Aliment Pharmacol Ther; 2006 Oct; 24(7):1087-97. PubMed ID: 16984503
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.